CCTG-PR26: A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Objective

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better or worse than the usual approach for prostate cancer. The usual approach for patients who are not in a study is hormone treatment with Androgen Deprivation Therapy (ADT) and Androgen-Receptor Pathway Inhibitor (ARPI).

National Clinical Trial (NCT) Number: 06592924

National Library of Medicine clinicaltrials.gov Website Address: https://clinicaltrials.gov/study/NCT06592924

Location: Essentia Health Cancer Centers

Research Study Categories

• Adult Oncology Studies

Specialties

• Genitourinary Cancer

Contact

Cancer Clinical Trials at 218-786-3308 or 844-681-7944, [email protected]